Document is current
Any future updates will be listed below
-
Authors
Bauer, Todd M
Santoro, Armando https://orcid.org/0000-0003-1709-9492
Lin, Chia-Chi https://orcid.org/0000-0002-2573-5789
Garrido-Laguna, Ignacio
Joerger, Markus
Greil, Richard
Spreafico, Anna https://orcid.org/0000-0002-3034-3042
Yau, Thomas
Goebeler, Maria-Elisabeth
Hütter-Krönke, Marie Luise
Perotti, Antonella
Juif, Pierre-Eric https://orcid.org/0000-0002-4899-8768
Lu, Darlene
Barys, Louise
Cremasco, Viviana
Pelletier, Marc
Evans, Helen
Fabre, Claire
Doi, Toshikiko
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02947165 at ClinicalTrials.govnct03436563 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
https://doi.org/10.1136/jitc-2023-007353
Documents that mention this clinical trial
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
https://doi.org/10.1136/jitc-2023-007353
BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer
https://doi.org/10.1136/bmjopen-2020-047831
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (N/A)
- License Information
